You are here

VLA15

Pfizer ticks off Lyme vaccine milestone, linking booster shot to pediatric antibody response

Pfizer ticks off Lyme vaccine milestone, linking booster shot to pediatric antibody response

Fierce Biotech

clinical trials

Flag link:

Valneva, Pfizer delay end date of Lyme disease vaccine phase 3 trial to 2025

Valneva, Pfizer delay end date of Lyme disease vaccine phase 3 trial to 2025

Seeking Alpha

clinical trials

Flag link:

Pfizer, Valneva remove half of participants from study of Lyme disease shot

Pfizer, Valneva remove half of participants from study of Lyme disease shot

BioPharma Dive

clinical trials

Flag link:

Pfizer and Valneva Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15

Pfizer and Valneva Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15

BioSpace

clinical trials

Flag link:

Valneva and Pfizer report positive Phase 2 data for Lyme disease vaccine in children

Valneva and Pfizer report positive Phase 2 data for Lyme disease vaccine in children

Biopharma Reporter

clinical trials

Flag link:

Pfizer's $130M Lyme disease vaccine advances to phase 3 after 3rd shot shown to increase antibodies

Pfizer's $130M Lyme disease vaccine advances to phase 3 after 3rd shot shown to increase antibodies

Fierce Biotech

clinical trials

Flag link:

Valneva, hit by COVID contract chaos, sees Lyme disease vaccine drop-off in phase 2, but boosters helping

Valneva, hit by COVID contract chaos, sees Lyme disease vaccine drop-off in phase 2, but boosters helping

Fierce Biotech

clinical trials

Flag link:

Valneva and Pfizer start new Phase 2 study for Lyme disease vaccine candidate

Valneva and Pfizer start new Phase 2 study for Lyme disease vaccine candidate

Biopharma Reporter

clinical trials

Flag link:

Can a new Lyme disease vaccine overcome a history of distrust and failure?

Can a new Lyme disease vaccine overcome a history of distrust and failure?

Stat

drug development

Flag link: